• CD28 targeting
  • How it works
AACR-2023 NI-2901 (CD47xPD-L1) & NI-3201 (CD28xPD-L1) bispecific antibodies

AACR-2023 NI-2901 (CD47xPD-L1) & NI-3201 (CD28xPD-L1) bispecific antibodies

AACR Annual Meeting 2023 - Walter Ferlin & Xavier Chauchet -


The American Association for Cancer Research (AACR), the largest cancer research organization, will host its Annual Meeting April 14-19, 2023. Light Chain Bioscience is very pleased to have Walter Ferlin and Xavier Chauchet attend in-person.

Walter Ferlin (CSO) and Xavier Chauchet (Project Leader) will be presenting posters (#2951 & #2973), describing our bispecific antibodies, NI-2901 (CD47xPD-L1) and NI-3201 (CD28xPD-L1).

aa

“NI-2901, an affinity-optimized CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade” will be exposed and presented on April 17 between 1:30 p.m -5:00 p.m. | section 23

Read poster - Poster #2951/29 [PDF]: 

aacr 2023 ni 2901 cd47xpd l1 bispecific antibodies scan

“NI-3201, a PD-L1xCD28 bispecific antibody for immune checkpoint-dependent CD28 co-stimulation” will be exposed and presented on April 17 between 1:30 p.m -5:00 p.m.| section 24

Read poster - Poster #2973/20 [PDF]: 

aacr 2023 ni 3201 checkpoint dependent cd28 costimulation scan 2


Ernest N. Morial Convention Center New Orleans, Louisiana

900 Convention Center Blvd, New Orleans, LA 70130, United States

Back to News

New publication in Cancer Immunology Research

NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control

Read more

LinkedIn